2 Health Care Equipment Stocks Analysts Rate Highly

Wednesday, Jul 22, 2026

Healthcare spending continues to prove remarkably resilient, but within the medical device sector, institutional focus is narrowing toward companies with clear technological moats and dependable clinical demand. Rather than chasing speculative concepts, Wall Street analysts are converging on established leaders that drive routine, essential procedures across major hospital systems. This disciplined focus has highlighted two dominant medical technology providers that currently command top buy ratings from Wall Street research desks. Both sit at the core of modern surgical and therapeutic care, backed by exceptionally strong analyst conviction.

👉 One is a global leader in minimally invasive interventional technologies, driving growth across specialized cardiovascular, endosurgery, and neuromodulation procedures.

👉 The other is a healthcare technology powerhouse deploying advanced medical therapies across broad cardiovascular, surgical, neuroscience, and diabetes care portfolios.

👉 Both hold deeply embedded positions across global healthcare networks and currently earn strong buy consensus ratings from Wall Street analysts.

In this edition, we break down Boston Scientific Corporation (BSX) and Medtronic plc (MDT) — Health Care Equipment versus Health Care Equipment under today's Top medical device stocks backdrop.

Hidden in Tesla's Filing: A $12 Billion "Super Startup"

Pull up Tesla's most recent SEC filing. Page 5.

And you'll see a single line showing $12 billion in revenue from a brand-new "super startup" Elon Musk has been quietly incubating inside Tesla.

This new "super startup" has nothing to do with cars or robots or space or AI...

But it sits at the center of what Blackstone calls "a $23 trillion investment opportunity."

And on July 22, Elon is expected to pull back the curtain and reveal exactly what he's building.

But Adam O'Dell already knows... and he reveals it all in this urgent video.

Our 1st Stock is

Boston Scientific Corporation (NYSE: BSX)

Boston Scientific Corporation (NYSE: BSX) is a global leader in the medical device sector, specializing in minimally invasive interventional medical technologies. Operating within the Health Care Equipment sub-industry, the company develops solutions across cardiovascular, endosurgery, and neuromodulation domains. Despite a steep 1-year price drop of approximately 55% to $45.29 per share, BSX maintains a prominent position backed by key product franchises such as its WATCHMAN left atrial appendage closure device. The stock retains significant liquidity, averaging over 30 million shares in daily trading volume.

Business Model and Revenue Streams 📦

Boston Scientific operates primarily through two segments: MedSurg and Cardiovascular. Revenue is generated globally through the direct sale and distribution of specialized medical devices to hospitals, outpatient facilities, and healthcare providers. Core offerings include structural heart solutions, cardiac rhythm management systems, electrophysiology technology, vascular therapies, and endoscopic instruments.

The business model relies heavily on single-use consumables and specialized implantable devices that drive recurring revenue tied directly to procedure volumes. Boston Scientific sustains its market position by reinvesting in high-margin, high-growth categories—particularly structural heart treatments and atrial fibrillation solutions—supported by a direct global commercial infrastructure.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

• Revenue for the quarter ended March 31, 2026 reached $5.203 billion, reflecting a YoY growth rate of 11.58%.

• Net income for the quarter ended March 31, 2026 was reported at $1.337 billion, yielding an EPS of $0.90.

• Trailing twelve months (TTM) valuation metrics include a P/E ratio of 18.87 and a P/S ratio of 3.27.

• The trailing EV/EBITDA ratio stands at 13.02 alongside a TTM PEG ratio of 0.24.

Strategic Initiatives and Mergers: 🤝

Boston Scientific's key operational initiatives focus on expanding market adoption for its core growth platforms. Key upcoming milestones include the Q2 2026 earnings release and WATCHMAN demand update scheduled for August 6, 2026. Additionally, court motions and developments regarding Farapulse class action litigation are slated for September 15, 2026, marking an important legal and operational watch point for the business.

Profitability and Fair Value 🎯

In the quarter ended March 31, 2026, Boston Scientific delivered revenue of $5.20 billion, representing 11.58% year-over-year growth, alongside net income of $1.34 billion and EPS of $0.90. Top-line expansion continues to be anchored by core cardiovascular and device categories, though profitability faces ongoing headwinds from cost inflation and updated corporate guidance.\n\nValuation metrics reflect a significant pullback, with shares down 55.75% over the past year to $45.29. Trailing twelve-month ratios show a P/E of 18.87, a P/S of 3.27, an EV/EBITDA of 13.02, and a PEG ratio of 0.24. Following the sharp drop from prior highs, these multiples position the company at a relatively compressed valuation compared to broader health care equipment peers.

Analyst Estimates and Ratings 📊

Wall Street consensus on Boston Scientific remains solidly bullish, consisting of 20 Buy ratings and 1 Hold rating. The latest street action is rated at Buy, though packet data confirms zero buy-side upgrades onto Buy or Strong Buy over the past 90 days. Analyst focus centers on near-term execution and demand trends across key device lines.

Investor-Focused Takeaway: Is BSX Right for Your Portfolio?

What to Watch in the Near Term: 📈

• Q2 2026 Earnings Release and WATCHMAN Demand Update scheduled for August 6, 2026.

• Farapulse Class Action Litigation Update and Court Motions on September 15, 2026.

• Q3 2026 Earnings Release scheduled for November 2, 2026.

• Management updates regarding full-year guidance recalibration and input cost pressures.

Recommendation:

Boston Scientific offers a balanced narrative of steady 11.58% quarterly revenue growth against a steep year-over-year share price drawdown. While low trailing valuation ratios present potential long-term value, ongoing litigation around Farapulse and margin pressure require close monitoring. This analysis is provided for educational purposes only and is not personalized investment advice.

Why Wall Street is Dumping ETFs - May 29th

What does the "smart money" know that you don't? On May 29, a 90-year-old law could shake the global gold market. While retail investors sit in ETFs, institutions are quietly buying a little-known "shadow miner." It can move 10x faster than gold.

See the filings and the ticker >>>

Our 2nd Stock is

Medtronic plc (NYSE: MDT)

Medtronic plc (NYSE: MDT) is a global healthcare technology leader operating within the Health Care Equipment sub-industry. The company develops, manufactures, and markets medical technology and therapies across cardiovascular, surgical, neuroscience, and diabetes portfolios. Trading near $79.34 with an average volume exceeding 8.2 million shares, Medtronic provides broad commercial scale and steady dividend performance within the medtech landscape.

Business Model and Revenue Streams 📦

Medtronic generates revenue primarily by designing and selling specialized medical devices, therapies, and equipment to hospitals, physicians, and healthcare systems globally. Its primary business spans core segments including Cardiovascular, Neuroscience, Medical-Surgical, and Diabetes care, delivering multi-faceted growth opportunities across diverse clinical categories.

The business model relies heavily on long-term clinical relationships, surgical consumable replenishment, and specialized medical hardware. By deploying capital into high-margin technologies and maintaining a extensive international distribution footprint, Medtronic builds deep institutional integration across global operating rooms and outpatient settings.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

• Quarter ended 2026-04-24 revenue reached $9.81 billion, delivering 9.86% year-over-year revenue growth.

• Quarter ended 2026-04-24 net income stood at $1.24 billion, resulting in an EPS of $0.98.

• Trailing twelve months valuation metrics reflect a P/E TTM of 21.96 and a P/S TTM of 2.90.

• EV/EBITDA TTM is reported at 13.52 with a TTM PEG ratio of 6.64.

Strategic Initiatives and Mergers: 🤝

Medtronic recently completed the acquisition of SPR, adding the SPRINT PNS platform to expand its minimally invasive, non-opioid pain therapy portfolio. Additionally, Medtronic announced its Touch Surgery Aide compute platform built on NVIDIA infrastructure, bringing FDA-cleared real-time AI decision support to robotic surgery.

Profitability and Fair Value 🎯

For the quarter ended April 24, 2026, Medtronic reported revenue of $9.81 billion, representing 9.86% year-over-year growth, along with net income of $1.24 billion and EPS of $0.98. Profitability continues to be fueled by high-margin medical devices and expanding platforms in robotic-assisted surgery and pain management following the strategic acquisition of SPR Therapeutics.

From a valuation perspective, MDT trades at a TTM P/E of 21.96, a TTM P/S of 2.90, and a TTM EV/EBITDA of 13.52. These multiples reflect a mature medical technology leader with solid cash generation and steady dividend aristocrat status, trading at fair levels relative to health care equipment peers as next-generation AI platforms roll out.

Analyst Estimates and Ratings 📊

Wall Street analyst consensus stands at 12 Buys and 6 Holds, with zero Sell ratings. The stock recently recorded 1 buy-side upgrade onto Buy/Strong Buy over the past 90 days, with the latest overall street action maintaining a Buy rating. Analysts highlight Medtronic's resilient product platforms and conservative forward guidance, with price targets ranging up to $92.

Investor-Focused Takeaway: Is MDT Right for Your Portfolio?

What to Watch in the Near Term: 📈

• Commercial adoption of the newly unveiled Touch Surgery Aide platform featuring FDA-cleared real-time AI.

• Integration and revenue contributions from the SPR Therapeutics acquisition and its SPRINT PNS technology.

• Q1 FY2027 financial results and guidance update scheduled for September 1, 2026.

• Cardiovascular portfolio clinical data disclosures at TCT 2026 and potential administration tariff assessments.

Recommendation:

Medtronic remains a steady, income-generating cornerstone within the medtech space, backed by reliable revenue growth and margin expansion via AI and robotic surgery innovations. While recent price action reflects broader sector shifts and potential tariff uncertainties, MDT offers balanced, low-volatility exposure for long-term health care allocation.

Jim Rickards: "This AI Company is the Next Lehman Brothers"

Jim Rickards just found this HUGE RED FLAG for AI stocks...

And you need to prepare now...

Because the last time he saw something like this was in 2008...

Three weeks before Lehman Brothers went under, triggering a market panic.

He believes this major AI company will go bust...

In a crisis that could be 10 times bigger than Lehman Brothers.

Final Take: Precision Innovation and Enterprise Scale in Medtech

The secular growth in medical devices is powered by two complementary forces: targeted interventional innovation that replaces traditional surgery, and massive commercial scale that supplies global health systems every day.

That is where Boston Scientific (BSX) and Medtronic (MDT) define the sector landscape.

🫀 Boston Scientific Corporation (BSX) — High-Growth Interventional Innovator

✔ Targeted market leadership in cardiovascular, MedSurg, and neuromodulation categories

✔ Driven by category-defining therapies like the WATCHMAN left atrial appendage closure device

✔ Focused portfolio strategy built on high-volume, minimally invasive interventional procedures

➤ Best for: Investors seeking pure-play exposure to high-margin, category-leading interventional medical technologies with strong procedural demand.

✔ Global commercial footprint spanning Cardiovascular, Neuroscience, Medical-Surgical, and Diabetes portfolios

✔ Deeply embedded hospital supply chains and direct-to-physician distribution networks

✔ Steady dividend performance backed by broad multi-segment revenue streams

➤ Best for: Investors wanting reliable, defensive healthcare exposure with consistent dividend income and comprehensive clinical coverage.

Investor Insight

🧩 Want pure-play innovation in high-value interventional procedures and structural growth? → BSX

⚙️ Want broad operational scale, multi-segment stability, and reliable dividend yield? → MDT

Bottom Line:

The medical device sector doesn't move on consumer cycles — it scales on procedural necessity, demographic tailwinds, and clinical efficacy.

Boston Scientific provides high-conviction exposure to specialized interventional breakthroughs, while Medtronic offers the bedrock scale and portfolio breadth necessary to navigate any macroeconomic environment. As healthcare systems globally prioritize procedural efficiency and improved patient outcomes, both BSX and MDT remain core holdings for comprehensive medtech exposure.

---

Research and education only. Not investment advice. Do your own research.